Literature DB >> 4632688

The alternate pathway of complement activation. The role of C3 and its inactivator (KAF).

P A Nicol, P J Lachmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4632688      PMCID： PMC1423020     

Source DB:  PubMed          Journal:  Immunology        ISSN： 0019-2805            Impact factor:   7.397


× No keyword cloud information.
  29 in total

1.  Antigenic determinants of human beta-1c and beta-1g-globulins.

Authors:  C West; N C Davis; J Forristal; J Herbst; R Spitzer
Journal:  J Immunol       Date:  1966-04       Impact factor: 5.422

2.  The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement.

Authors:  P J Lachmann; H J Müller-Eberhard
Journal:  J Immunol       Date:  1968-04       Impact factor: 5.422

3.  C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1969-03       Impact factor: 5.422

4.  A new concept of immunosuppression in hypersensitivity reactions and in transplantation immunity.

Authors:  R A Nelson
Journal:  Surv Ophthalmol       Date:  1966-08       Impact factor: 6.048

5.  Three naturally-occurring inhibitors of components of complement in guinea pig and rabbit serum.

Authors:  N Tamura; R A Nelson
Journal:  J Immunol       Date:  1967-09       Impact factor: 5.422

6.  The preparation and properties of alexinated intermediates that react with conglutinin. I. Guinea-pig complement.

Authors:  P J Lachmann; R Liske
Journal:  Immunology       Date:  1966-09       Impact factor: 7.397

7.  Alper CA, Rosen FS: Studies of the in vivo behavior of human C'3 in normal subjects and patients.

Authors:  C A Alper; F S Rosen
Journal:  J Clin Invest       Date:  1967-12       Impact factor: 14.808

8.  C3 leukotactic factors produced by a tissue protease.

Authors:  J H Hill; P A Ward
Journal:  J Exp Med       Date:  1969-09-01       Impact factor: 14.307

9.  A plasmin-split fragment of C'3 as a new chemotactic factor.

Authors:  P A Ward
Journal:  J Exp Med       Date:  1967-08-01       Impact factor: 14.307

10.  Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum.

Authors:  V A Bokisch; H J Müller-Eberhard; C G Cochrane
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307
View more
  53 in total

Review 1.  Complement deficiency.

Authors:  K M O'Neil
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

2.  Deficiency of factor B of the complement system in sickle cell anaemia.

Authors:  W A Wilson; G R Hughes; P J Lachmann
Journal:  Br Med J       Date:  1976-02-14

3.  Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.

Authors:  L H Perrin; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

4.  Recurrent infections in partial complement factor I deficiency: evaluation of three generations of a Brazilian family.

Authors:  A S Grumach; M F Leitão; V G Arruk; M Kirschfink; A Condino-Neto
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

5.  Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia.

Authors:  J A Charlesworth; D G Williams; E Sherington; P J Lachmann; D K Peters
Journal:  J Clin Invest       Date:  1974-06       Impact factor: 14.808

6.  Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency.

Authors:  J B Ziegler; C A Alper; R S Rosen; P J Lachmann; L Sherington
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

7.  C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.

Authors:  K Whaley; P H Schur; S Ruddy
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

8.  The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation.

Authors:  P J Lachmann; L Halbwachs
Journal:  Clin Exp Immunol       Date:  1975-07       Impact factor: 4.330

9.  Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins.

Authors:  M T Aguado; L H Perrin; R Ramirez; P A Miescher; P H Lambert
Journal:  Clin Exp Immunol       Date:  1980-12       Impact factor: 4.330

10.  Formation of C3-IgG complexes in serum by aggregated IgG and by non-immunoglobulin activators of complement.

Authors:  A P van Dam; C E Hack
Journal:  Immunology       Date:  1987-06       Impact factor: 7.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.